methylphenidate has been researched along with Anxiety Neuroses in 45 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Excerpt | Relevance | Reference |
---|---|---|
" Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls." | 7.85 | Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017) |
"There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment." | 7.75 | Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009) |
" Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls." | 3.85 | Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017) |
"There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment." | 3.75 | Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009) |
"Childhood narcolepsy is associated with various emotional, behavioural and cognitive dysfunctions as well as with psychiatric and neurodevelopmental disorders: anxiety, depression, attention deficit hyperactivity disorder and psychosis." | 1.48 | Childhood narcolepsy and autism spectrum disorders: four case reports. ( Dudova, I; Hrdlicka, M; Mohaplova, M; Nevsimalova, S; Prihodova, I, 2018) |
"The most common comorbidities were substance use disorders (39." | 1.43 | Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study. ( Balanzá-Martínez, V; García-García, P; Piñeiro-Dieguez, B; Soler-López, B, 2016) |
"In France, attention deficit disorder (ADHD) has traditionally met with two opposing approaches (biological and psychoanalytic)." | 1.37 | [Attention deficit disorder: multidisciplinary observational study over 1 year]. ( Billard, C; Chambry, J; Cohen de Lara, A; Delteil-Pinton, F; Guinard, M; Idiart, ME; Lacaze, E, 2011) |
"Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm." | 1.35 | Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. ( Akechi, T; Akizuki, N; Ito, T; Nakano, T; Okamura, M; Shimizu, K; Uchitomi, Y, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (13.33) | 18.7374 |
1990's | 5 (11.11) | 18.2507 |
2000's | 12 (26.67) | 29.6817 |
2010's | 20 (44.44) | 24.3611 |
2020's | 2 (4.44) | 2.80 |
Authors | Studies |
---|---|
Gaillard, C | 1 |
Lago, TR | 1 |
Gorka, AX | 1 |
Balderston, NL | 1 |
Fuchs, BA | 1 |
Reynolds, RC | 1 |
Grillon, C | 1 |
Ernst, M | 1 |
Boesen, K | 1 |
Paludan-Müller, AS | 1 |
Gøtzsche, PC | 1 |
Jørgensen, KJ | 1 |
Quinn, DK | 1 |
Mayer, AR | 1 |
Master, CL | 1 |
Fann, JR | 1 |
Suhaiban, H | 1 |
Javanbakht, A | 1 |
Prihodova, I | 1 |
Dudova, I | 1 |
Mohaplova, M | 1 |
Hrdlicka, M | 1 |
Nevsimalova, S | 1 |
Villas-Boas, CB | 1 |
Chierrito, D | 1 |
Fernandez-Llimos, F | 1 |
Tonin, FS | 1 |
Sanches, ACC | 1 |
Oliva, F | 1 |
Carezana, C | 1 |
Nibbio, G | 1 |
Bramante, S | 1 |
Portigliatti Pomeri, A | 1 |
Maina, G | 1 |
Bloch, Y | 2 |
Aviram, S | 1 |
Segev, A | 2 |
Nitzan, U | 1 |
Levkovitz, Y | 1 |
Braw, Y | 1 |
Mimouni Bloch, A | 1 |
Piñeiro-Dieguez, B | 1 |
Balanzá-Martínez, V | 1 |
García-García, P | 1 |
Soler-López, B | 1 |
Bottelier, MA | 1 |
Schouw, ML | 1 |
Klomp, A | 1 |
Tamminga, HG | 1 |
Schrantee, AG | 1 |
Bouziane, C | 1 |
de Ruiter, MB | 1 |
Boer, F | 1 |
Ruhé, HG | 1 |
Denys, D | 1 |
Rijsman, R | 1 |
Lindauer, RJ | 1 |
Reitsma, HB | 1 |
Geurts, HM | 1 |
Reneman, L | 1 |
Giacobini, M | 1 |
Medin, E | 1 |
Ahnemark, E | 1 |
Russo, LJ | 1 |
Carlqvist, P | 1 |
Lavretsky, H | 1 |
Reinlieb, M | 1 |
St Cyr, N | 1 |
Siddarth, P | 1 |
Ercoli, LM | 1 |
Senturk, D | 1 |
Gvirts, HZ | 1 |
Strouse, K | 1 |
Mayseless, N | 1 |
Gelbard, H | 1 |
Lewis, YD | 1 |
Barnea, Y | 1 |
Feffer, K | 1 |
Shamay-Tsoory, SG | 1 |
Mattingly, GW | 1 |
Anderson, RH | 1 |
Purper-Ouakil, D | 1 |
Garcia, SP | 1 |
Guimarães, J | 1 |
Zampieri, JF | 1 |
Martinez, AL | 1 |
Polanczyk, G | 1 |
Rohde, LA | 1 |
Warton, FL | 1 |
Howells, FM | 1 |
Russell, VA | 1 |
Gürkan, K | 1 |
Bilgiç, A | 1 |
Türkoglu, S | 1 |
Kiliç, BG | 1 |
Aysev, A | 1 |
Uslu, R | 1 |
Gadow, KD | 1 |
Nolan, EE | 1 |
Ter-Stepanian, M | 1 |
Grizenko, N | 1 |
Zappitelli, M | 1 |
Joober, R | 1 |
Gomes, KM | 1 |
Souza, RP | 1 |
Inácio, CG | 1 |
Valvassori, SS | 1 |
Réus, GZ | 1 |
Martins, MR | 1 |
Comim, CM | 1 |
Quevedo, J | 1 |
Marcus, SC | 1 |
Durkin, M | 1 |
Chambry, J | 1 |
Billard, C | 1 |
Guinard, M | 1 |
Lacaze, E | 1 |
Idiart, ME | 1 |
Delteil-Pinton, F | 1 |
Cohen de Lara, A | 1 |
Mattos, P | 1 |
Louzã, MR | 1 |
Palmini, AL | 1 |
de Oliveira, IR | 1 |
Rocha, FL | 1 |
Sánchez-Pérez, AM | 1 |
García-Avilés, Á | 1 |
Albert Gascó, H | 1 |
Sanjuán, J | 1 |
Olucha-Bordonau, FE | 1 |
Woolley, JB | 1 |
Heyman, I | 1 |
Serby, M | 1 |
ALAMANNI, V | 1 |
LING, TM | 1 |
BUCKMAN, J | 1 |
SPENCER, AM | 1 |
Janowsky, DS | 1 |
Nakane, A | 1 |
Quinn, PO | 1 |
Abikoff, H | 1 |
McGough, J | 1 |
Vitiello, B | 2 |
McCracken, J | 1 |
Davies, M | 2 |
Walkup, J | 1 |
Riddle, M | 1 |
Oatis, M | 1 |
Greenhill, L | 1 |
Skrobala, A | 2 |
March, J | 1 |
Gammon, P | 1 |
Robinson, J | 1 |
Lazell, R | 1 |
McMahon, DJ | 1 |
Ritz, L | 1 |
Okamura, M | 1 |
Akizuki, N | 1 |
Nakano, T | 1 |
Shimizu, K | 1 |
Ito, T | 1 |
Akechi, T | 1 |
Uchitomi, Y | 1 |
Posner, K | 1 |
Melvin, GA | 1 |
Murray, DW | 1 |
Gugga, SS | 1 |
Fisher, P | 1 |
Cunningham, C | 1 |
Abikoff, HB | 1 |
Ghuman, JK | 1 |
Kollins, S | 1 |
Wigal, SB | 1 |
Wigal, T | 1 |
McCracken, JT | 1 |
McGough, JJ | 1 |
Kastelic, E | 1 |
Boorady, R | 1 |
Chuang, SZ | 1 |
Swanson, JM | 1 |
Riddle, MA | 1 |
Greenhill, LL | 1 |
Bedard, AC | 1 |
Tannock, R | 3 |
Nissen, G | 1 |
Ickowicz, A | 1 |
Schachar, R | 1 |
Spencer, T | 2 |
Wilens, T | 1 |
Biederman, J | 2 |
Faraone, SV | 1 |
Ablon, JS | 1 |
Lapey, K | 1 |
Wilens, TE | 1 |
Wozniak, J | 1 |
Connor, D | 1 |
Diamond, IR | 1 |
Schachar, RJ | 1 |
Pliszka, SR | 1 |
Bojanovský, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety[NCT02153944] | Phase 4 | 142 participants (Actual) | Interventional | 2014-06-16 | Completed | ||
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity[NCT03481959] | Phase 3 | 3 participants (Actual) | Interventional | 2019-05-07 | Terminated (stopped due to insufficient recrutement in the study) | ||
Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)[NCT02675400] | Phase 4 | 19 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder[NCT00307684] | Phase 3 | 155 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD[NCT01338818] | Phase 3 | 299 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States[NCT04507204] | Phase 4 | 267 participants (Actual) | Interventional | 2020-07-30 | Terminated (stopped due to (due to administrative reasons not related to efficacy or safety.)) | ||
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)[NCT00483106] | Phase 4 | 885 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT04964427] | 26 participants (Actual) | Interventional | 2021-02-08 | Completed | |||
Multimodal Treatment Study of Children With ADHD[NCT00000388] | Phase 4 | 0 participants | Interventional | 1998-09-30 | Completed | ||
A Randomized Controlled Trial Into the Effectiveness of a Behavioral Teacher Program Targeting ADHD Symptoms[NCT02518711] | 114 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus zero seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.9565625 |
fMRI: Drug Challenge With Placebo | 0.919697 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 180 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.9529032 |
fMRI: Drug Challenge With Placebo | 0.953125 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.725625 |
fMRI: Drug Challenge With Placebo | 0.739697 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 215 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.7570968 |
fMRI: Drug Challenge With Placebo | 0.7428125 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 90 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.9228125 |
fMRI: Drug Challenge With Placebo | 0.9378788 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 260 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.9435484 |
fMRI: Drug Challenge With Placebo | 0.9425 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 135 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.73 |
fMRI: Drug Challenge With Placebo | 0.7275758 |
Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). Two levels of difficulties were tested: 1- and 3-back. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block represented a given level of difficulty, i.e., 1- and 3-back. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 305 seconds within a 6-hour study visit
Intervention | Proportion of correct responses (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 0.7816129 |
fMRI: Drug Challenge With Placebo | 0.7671875 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition( threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus zero seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 743.283125 |
fMRI: Drug Challenge With Placebo | 794.7833333 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 180 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 707.7925806 |
fMRI: Drug Challenge With Placebo | 741.5425 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 976.1853125 |
fMRI: Drug Challenge With Placebo | 1007.74 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 215 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 912.6574194 |
fMRI: Drug Challenge With Placebo | 915.005625 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 90 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 771.2671875 |
fMRI: Drug Challenge With Placebo | 779.1712121 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 260 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 729.0251613 |
fMRI: Drug Challenge With Placebo | 735.5509375 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 135 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 971.676875 |
fMRI: Drug Challenge With Placebo | 995.619697 |
Reaction time (RT) is the time it takes to respond to stimuli. Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block. Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks. RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA. (NCT02153944)
Timeframe: 90 minutes plus 305 seconds within a 6-hour study visit
Intervention | milliseconds (ms) (Mean) |
---|---|
fMRI: Drug Challenge With Methylphenidate | 925.3409677 |
fMRI: Drug Challenge With Placebo | 929.6796875 |
"The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Participants responded with a button press. The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone. The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye." (NCT02153944)
Timeframe: 20-120 milliseconds following the onset of the startle stimulus
Intervention | millivolts (mV) (Mean) | ||
---|---|---|---|
1Back | 2Back | 3Back | |
Behavioral: Drug Challenge With Methylphenidate | 42.2880893 | 44.1886408 | 45.7608354 |
Behavioral: Drug Challenge With Placebo | 42.39801 | 45.32989 | 46.63108 |
Behavioral: Drug Challenge With Propranolol | 43.61243 | 44.96692 | 47.15858 |
"The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Participants responded with a button press. The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone. The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye." (NCT02153944)
Timeframe: 20-120 milliseconds following the onset of the startle stimulus
Intervention | millivolts (mV) (Mean) | ||
---|---|---|---|
1Back | 2Back | 3Back | |
Behavioral: Drug Challenge With Methylphenidate | 51.6813833 | 51.0953725 | 52.1700802 |
Behavioral: Drug Challenge With Placebo | 51.79882 | 51.61492 | 51.40215 |
Behavioral: Drug Challenge With Propranolol | 52.20783 | 50.13929 | 50.53474 |
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 360 seconds within a 6-hour study visit
Intervention | arbitrary units (A.U) (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Brain Cluster-001 - Posterior Cingulate Cortex (PCC) | Brain Cluster-002 - Right Prefrontal Cortex (PFC) | Brain Cluster-003 - Left Prefrontal Cortex (PFC) | Brain Cluster-004 - Anterior Cingulate Cortex (ACC) | Brain Cluster-009 - Right Putamen | Brain Cluster-11 - Frontal Pole | Brain Cluster-12 - Right Insula | Brain Cluster-13 - Frontal Pole | Brain Cluster-14-Right Insula | |
fMRI: Drug Challenge With Methylphenidate | -0.1725431 | -0.0806112 | -0.1557721 | -0.1201138 | -0.06733 | -0.0929706 | -0.0543121 | -0.1420901 | -0.0580487 |
fMRI: Drug Challenge With Placebo | -0.1488312 | -0.0609964 | -0.1297947 | -0.0940195 | -0.0435053 | -0.0173495 | -0.0434811 | -0.0822257 | -0.0542862 |
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 450 seconds within a 6-hour study visit
Intervention | arbitrary units (A.U) (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Brain Cluster-001 - Posterior Cingulate Cortex (PCC) | Brain Cluster-002 - Right Prefrontal Cortex (PFC) | Brain Cluster-003 - Left Prefrontal Cortex (PFC) | Brain Cluster-004 - Anterior Cingulate Cortex (ACC) | Brain Cluster-009 - Right Putamen | Brain Cluster-11 - Frontal Pole | Brain Cluster-12 - Right Insula | Brain Cluster-13 - Frontal Pole | Brain Cluster-14-Right Insula | |
fMRI: Drug Challenge With Methylphenidate | -0.0884053 | -0.0248587 | -0.0465762 | -0.089146 | -0.0470163 | -0.037367 | -0.0549414 | -0.1711822 | -0.0592526 |
fMRI: Drug Challenge With Placebo | -0.1575204 | -0.0701165 | -0.0900214 | -0.1278046 | -0.0758935 | -0.022933 | -0.0925233 | -0.1896215 | -0.0882445 |
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus 90 seconds within a 6-hour study visit
Intervention | arbitrary units (A.U) (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Brain Cluster-001 - Posterior Cingulate Cortex (PCC) | Brain Cluster-002 - Right Prefrontal Cortex (PFC) | Brain Cluster-003 - Left Prefrontal Cortex (PFC) | Brain Cluster-004 - Anterior Cingulate Cortex (ACC) | Brain Cluster-009 - Right Putamen | Brain Cluster-11 - Frontal Pole | Brain Cluster-12 - Right Insula | Brain Cluster-13 - Frontal Pole | Brain Cluster-14 - Right Insula | |
fMRI: Drug Challenge With Methylphenidate | -0.151002 | -0.0712797 | -0.1331336 | -0.1140823 | -0.0501889 | -0.0928793 | -0.0349776 | -0.1301602 | -0.0431302 |
fMRI: Drug Challenge With Placebo | -0.2039758 | -0.1167484 | -0.1876725 | -0.151052 | -0.0848515 | -0.0743447 | -0.0830865 | -0.1309601 | -0.0856204 |
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner. The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI). Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task. The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. Two levels of difficulties were tested: 1Back and 3Back (n-back). Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back. (NCT02153944)
Timeframe: started 90 minutes post drug administration plus up to 270 seconds within a 6-hour study visit
Intervention | arbitrary units (A.U) (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Brain Cluster-001 - Posterior Cingulate Cortex (PCC) | Brain Cluster-002 - Right Prefrontal Cortex (PFC) | Brain Cluster-003 - Left Prefrontal Cortex (PFC) | Brain Cluster-004 - Anterior Cingulate Cortex (ACC) | Brain Cluster-009 - Right Putamen | Brain Cluster-11 - Frontal Pole | Brain Cluster-12 - Right Insula | Brain Cluster-13 - Frontal Pole | Brain Cluster-14 - Right Insula | |
fMRI: Drug Challenge With Methylphenidate | -0.1255616 | -0.0557781 | -0.0797764 | -0.1212111 | -0.0716675 | -0.0695188 | -0.0868275 | -0.2002039 | -0.0783793 |
fMRI: Drug Challenge With Placebo | -0.1256943 | -0.0542905 | -0.0719455 | -0.1206337 | -0.0560306 | 0.001909 | -0.0971834 | -0.1695771 | -0.0832567 |
The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit. (NCT02153944)
Timeframe: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
Intervention | beats/minute (Mean) | ||
---|---|---|---|
20 minutes after arrival for study | 10 minutes post drug administration | 145 minutes post drug administration | |
fMRI: Drug Challenge With Methylphenidate | 79.0294118 | 72.1818182 | 74.3030303 |
fMRI: Drug Challenge With Placebo | 77.2941176 | 72.6470588 | 69.7647059 |
The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit. (NCT02153944)
Timeframe: 20 minutes after arrival for study; 80 minutes & 125 minutes post drug administration
Intervention | beats/minute (Mean) | ||
---|---|---|---|
20 minutes after arrival for study | 80 minutes post drug administration | 125 minutes post drug administration | |
Behavioral: Drug Challenge With Methylphenidate | 72.8 | 73.6 | 75.75 |
Behavioral: Drug Challenge With Placebo | 74.35 | 75.1 | 72.45 |
Behavioral: Drug Challenge With Propranolol | 66.35 | 64.6 | 60.05 |
"The level of anxiety was assessed using the State Anxiety Inventory questionnaire. The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety. The State Anxiety Scale has 20 items. All items are rated on a 4-point scale ranging from 1 = not at all to 4 = very much so. The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety. State Anxiety score was measured at different time points during the study." (NCT02153944)
Timeframe: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
Intervention | Units on a scale (Mean) | ||
---|---|---|---|
20 minutes after arrival for study | 10 minutes post drug administration | 145 minutes post drug administration | |
fMRI: Drug Challenge With Methylphenidate | 24.6363636 | 27.2352941 | 32.4705882 |
fMRI: Drug Challenge With Placebo | 23.1818182 | 24.2352941 | 29.6969697 |
"The level of anxiety was assessed using the State Anxiety Inventory questionnaire. The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety. The State Anxiety Scale has 20 items. All items are rated on a 4-point scale ranging from 1 = not at all to 4 = very much so. The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety. State Anxiety score was measured at different time points during the study." (NCT02153944)
Timeframe: 20 minutes after arrival for study; 80, 100, & 125 minutes post drug administration
Intervention | Units on a scale (Mean) | |||
---|---|---|---|---|
20 minutes after arrival for study | 80 minutes post drug administration | 100 minutes post drug administration | 125 minutes post drug administration | |
Behavioral: Drug Challenge With Methylphenidate | 26.35 | 25.75 | 36.4 | 34.15 |
Behavioral: Drug Challenge With Placebo | 25.7 | 25.5 | 36.2 | 33.25 |
Behavioral: Drug Challenge With Propranolol | 27.65 | 28.3 | 37.9 | 34.31579 |
"Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA." (NCT02153944)
Timeframe: Task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
Intervention | Proportion of correct responses (Mean) | ||
---|---|---|---|
1Back | 2Back | 3Back | |
Behavioral: Drug Challenge With Methylphenidate | 0.96235 | 0.92585 | 0.82115 |
Behavioral: Drug Challenge With Placebo | 0.9285 | 0.8734 | 0.792 |
Behavioral: Drug Challenge With Propranolol | 0.94535 | 0.9039 | 0.8528 |
"Stimuli were presented one at a time on a screen. Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe). The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually. The participant holds each stimulus in short-term memory while new stimuli are presented. For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding yes if the stimulus currently presented matches the stimulus presented earlier. Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA." (NCT02153944)
Timeframe: task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
Intervention | Proportion of correct responses (Mean) | ||
---|---|---|---|
1Back | 2Back | 3Back | |
Behavioral: Drug Challenge With Methylphenidate | 0.9586 | 0.88505 | 0.8358 |
Behavioral: Drug Challenge With Placebo | 0.92755 | 0.83255 | 0.74575 |
Behavioral: Drug Challenge With Propranolol | 0.94445 | 0.88275 | 0.8152 |
"To evaluate maintenance of treatment effects of PR OROS MPH vs. placebo as measured on CAARS.~CAARS assesses ADHD symptoms and behaviors in adults. best value: 0 worst value: 54~Endpoint: last available post-baseline assessment." (NCT00307684)
Timeframe: DB baseline, DB endpoint
Intervention | units on a scale (Mean) |
---|---|
Active | 4.0 |
Placebo | 6.5 |
Evaluation of treatment effects as rated by the subjects on the CAARS-S:S. best score: 0 worst score: 104 (NCT00307684)
Timeframe: DB baseline, DB endpoint
Intervention | units on a scale (Mean) |
---|---|
Active | 4.4 |
Placebo | 4.0 |
evaluation of treatment effects as rated by the investigator on the CGI-S scale. CGI-S is used to rate the severity of a subject's illness on a 7- point scale ranging from 1 (not ill) to 7 (extremely severe). (NCT00307684)
Timeframe: DB baseline, DB endpoint
Intervention | units on a scale (Mean) |
---|---|
Active | 0.6 |
Placebo | 1.0 |
Assessment of the long term effect on overall functioning measured by CGI-S best score: 1 worst score: 7 (NCT00307684)
Timeframe: OL baseline, OL endpoint
Intervention | units on a scale (Mean) |
---|---|
Open Label PR OROS MPH | -0.3 |
Quality of life measured by Q-LES-Q best score: 100 worst score: 0 (NCT00307684)
Timeframe: OL baseline, OL endpoint
Intervention | units on a scale (Mean) |
---|---|
Open Label PR OROS MPH | 1.4 |
"Long term efficacy of PR OROS MPH as assessed by investigator-rated CAARS total score, hyperactivity/impulsivity subscale score and inattention subscale score.~Subscale scores: best value: 0, worst value: 27" (NCT00307684)
Timeframe: OL baseline, OL endpoint
Intervention | units on a scale (Mean) | ||
---|---|---|---|
change from baseline to endpoint in total score | change from baseline to endpoint in inattention | change from baseline to endpoint in hyperactivity | |
Open Label PR OROS MPH | -1.9 | -1.0 | -0.9 |
To evaluate the long term safety and tolerability of PR OROS MPH (18, 36, 54, 72 and 90 mg/day) in adults with Attention Deficit Hyperactivity Disorder (ADHD) (NCT00307684)
Timeframe: Treatment duration for OL extended from 52 wks to 72 wks (International Amendment 2) or 108 wks in Germany. Treatment duration for double-blind (DB) randomized withdrawal: 4 weeks
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
at least one AE | at least one SAE | at least one severe AE | at least one AE leading to permanent stop | at least one AE leading to temporary stop | at least one AE with concomitant therapy | at least one AE at least possibly related | |
Active | 7 | 0 | 0 | 0 | 0 | 0 | 3 |
Open Label PR OROS MPH | 126 | 12 | 27 | 15 | 23 | 93 | 62 |
Placebo | 8 | 1 | 3 | 0 | 2 | 4 | 5 |
"Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) total score consists of 18 items directly adapted from the ADHD symptom list according to the DSM-IV. The DSM-IV ADHD RS total score was calculated as the sum of the Inattentive and the Hyperactive-Impulsive subscores. The 18 items are rated from 0 (rarely or never) to 3 (Very often). The total score ranges from 0 to 54. Decrease in the DSM-IV ADHD RS total score indicates improvement, therefore a greater decrease (change at Final Visit compared to baseline) indicates a greater improvement in ADHD symptoms. Last Observation Carried Forward (LOCF) applied for each patient with data in extension period. If no post-baseline is available, it is considered as missing." (NCT01338818)
Timeframe: week 40 - week 66
Intervention | scores on a scale (Mean) |
---|---|
Ritalin LA | -7.2 |
SDS,5-self-rated questionnaire to measure the extent a pt's disability due to an illness/health problem interferes with work/school,social life/leisure,family life/home. First 3 items, pts are asked how their symptoms disrupted their regular activities over the past 7d in each using a scale from 0(not at all)-10(extremely) Each subscale(work disability, social life disability, family life disability)can be scored independently or combined into a total score(sum of the non-missing responses for items 1-3)from 0-30,higher scores indicate significant functional impairment. Subscale scores>5 suggest impairment in that subscale area. Final 2 items ask pts about the # of days their symptoms caused them to miss school/work and # of days their symptoms caused them to be underproductive at school/work.(These items were not included in the total score.) Before responding to SDS items 1-3, pts were verbally instructed to recall the past 7d, items 4-5 refer to the last week w/in the item wording. (NCT01338818)
Timeframe: week 40 - week 66
Intervention | Scores on a scale (Mean) |
---|---|
Ritalin LA | -4.8 |
Adverse Events, Serious Adverse Events and Deaths were monitored from week 40 to week 66. (NCT01338818)
Timeframe: Week 40 - Week 66
Intervention | participants (Number) | ||
---|---|---|---|
Adverse Events (Serious and Non Serious) | Serious Adverse Events | Deaths | |
Ritalin LA | 208 | 2 | 0 |
TASS was completed at the end of waking hours (14 - 16 hours post-dosing) at Month-2 after baseline visit. TASS was developed to capture the change in ADHD symptoms over the course of a day and consists of 18 items that directly correspond to the 18 ADHD symptom domains listed in the DSM-5. Each item is scored on a 4-point scale as follows: 0 (none), 1 (mild), 2 (moderate), and 3 (severe); the maximum total score is 54. A higher total score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Month-2
Intervention | score on a scale (Least Squares Mean) |
---|---|
Adhansia XR | 20.2 |
Concerta | 22.1 |
Used to assess health-related quality of life for adult patients. The AAQoL yields a total score based on 29 items. The raw scores are transformed to a 0 to 100 scale with higher scores indicating a better quality of life. (NCT04507204)
Timeframe: Baseline, Months -1, -2, -3, -4, -5 and -6
Intervention | score on a scale (Least Squares Mean) | ||||||
---|---|---|---|---|---|---|---|
Total Score at Baseline | Total Score at Month 1 | Total Score at Month 2 | Total Score at Month 3 | Total Score at Month 4 | Total Score at Month 5 | Total Score at Month 6 | |
Adhansia XR | 41.1 | 55.5 | 63.0 | 63.4 | 64.7 | 66.3 | 67.4 |
Concerta | 41.1 | 55.0 | 59.1 | 60.9 | 61.8 | 60.2 | 63.6 |
The CGI-I measures global improvement prior to and after initiating the study medication. The CGI-I scale is 1 question, and rates improvement compared with the baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Month-2, Month-4, and Month-6
Intervention | score on a scale (Least Squares Mean) | ||
---|---|---|---|
Month 2 | Month 4 | Month 6 | |
Adhansia XR | 2.3 | 2.0 | 2.0 |
Concerta | 2.3 | 2.2 | 2.3 |
The CGI-S rates symptoms from 1 (not ill) to 7 (extremely ill). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Baseline, Month-2, Month-4, and Month-6
Intervention | score on a scale (Least Squares Mean) | |||
---|---|---|---|---|
Baseline | Month 2 | Month 4 | Month 6 | |
Adhansia XR | 4.6 | 3.1 | 2.7 | 2.7 |
Concerta | 4.6 | 3.2 | 3.0 | 3.1 |
"The Treatment Satisfaction Questionnaire for Medications (TSQM) measures a patient's level of satisfaction or dissatisfaction with the study medication. It assesses perceptions of effectiveness, side effects and convenience of the medication and consists of 14 items that evaluate these three domains and one global scale item (ie, global satisfaction). Scores for each domain are computed by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100.~A lower score indicates a lower satisfaction with treatment." (NCT04507204)
Timeframe: Month-1, Month-2, and Month-6
Intervention | score on a scale (Least Squares Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Global Satisfaction at Month 1 | Global Satisfaction at Month 2 | Global Satisfaction at Month 6 | Effectiveness at Month 1 | Effectiveness at Month 2 | Effectiveness at Month 6 | Side Effects at Month 1 | Side Effects at Month 2 | Side Effects at Month 6 | Convenience at Month 1 | Convenience at Month 2 | Convenience at Month 6 | |
Adhansia XR | 84.8 | 85.2 | 86.2 | 51.3 | 61.1 | 63.9 | 74.0 | 72.0 | 70.7 | 58.9 | 57.0 | 59.7 |
Concerta | 84.3 | 82.8 | 84.3 | 52.4 | 58.8 | 61.9 | 69.6 | 67.6 | 74.1 | 59.2 | 58.7 | 57.0 |
The ADHD-RS-5 assesses the frequency and severity of each of the 18 ADHD symptoms among adults based on DSM-5 criteria. Each of the 18 DSM-5 symptoms are rated on a 4 point scale from 0 (never or rarely) to 3 (very often), yielding a total score of 0 to 54. A higher score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Baseline to Month-2
Intervention | score on a scale (Mean) | |
---|---|---|
Total Score at baseline | Total Score at Month 2 | |
Adhansia XR | 34.6 | 18.7 |
A comparison of the frequency of health care encounters between the 2 treatment groups. Healthcare resource utilization were evaluated monthly by comparing the frequency of clinic visits (outpatient), inpatient/hospitalizations (and length of stay), and emergency department visits between the 2 treatment groups. (NCT04507204)
Timeframe: Baseline (past 6 months) Months -2, -4, and -6
Intervention | Visits or Inpatient Admissions (Least Squares Mean) | |||
---|---|---|---|---|
Baseline (past 6 months) Overall Total Visits or Inpatient Admissions | Month 2 - Overall Total Visits or Inpatient Admissions | Month 4 - Overall Total Visits or Inpatient Admissions | Month 6 - Overall Total Visits or Inpatient Admissions | |
Adhansia XR | 2.14 | 2.26 | 1.67 | 1.34 |
Concerta | 2.93 | 2.43 | 1.73 | 1.85 |
"The PSQI is an instrument used to measure the quality and patterns of sleep; It differentiates poor from good sleep. It is filled out by the caregiver or the patient and the global sum score ranges from 0 to 21, with higher scores indicating worse sleep quality." (NCT04507204)
Timeframe: Baseline and Months -2, -4, and -6
Intervention | score on a scale (Least Squares Mean) | |||
---|---|---|---|---|
Global PSQI - Baseline | Global PSQI - Month 2 | Global PSQI - Month 4 | Global PSQI - Month 6 | |
Adhansia XR | 9.68 | 7.92 | 8.11 | 7.92 |
Concerta | 9.59 | 9.59 | 7.76 | 7.80 |
The WPAI questionnaire is designed to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It consists of 4 domains [absenteeism (missing work), presenteeism (impaired productivity at work), overall work performance (combined absenteeism and presenteeism), and non-work activities (activity impairment)]. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. (NCT04507204)
Timeframe: Baseline, Months -2, -3, -4, -5, and -6
Intervention | percentage of impairment (Least Squares Mean) | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percent work time missed due to health (Absenteeism) - Baseline | Percent work time missed due to health (Absenteeism) - Month 2 | Percent work time missed due to health (Absenteeism) - Month 3 | Percent work time missed due to health (Absenteeism) - Month 4 | Percent work time missed due to health (Absenteeism) - Month 5 | Percent work time missed due to health (Absenteeism) - Month 6 | Percent impairment while working due to health (Presenteeism) - Baseline | Percent impairment while working due to health (Presenteeism) - Month 2 | Percent impairment while working due to health (Presenteeism) - Month 3 | Percent impairment while working due to health (Presenteeism) - Month 4 | Percent impairment while working due to health (Presenteeism) - Month 5 | Percent impairment while working due to health (Presenteeism) - Month 6 | Percent overall work impairment due to health - Baseline | Percent overall work impairment due to health - Month 2 | Percent overall work impairment due to health - Month 3 | Percent overall work impairment due to health - Month 4 | Percent overall work impairment due to health - Month 5 | Percent overall work impairment due to health - Month 6 | Percent activity impairment due to health - Baseline | Percent activity impairment due to health - Month 2 | Percent activity impairment due to health - Month 3 | Percent activity impairment due to health - Month 4 | Percent activity impairment due to health - Month 5 | Percent activity impairment due to health - Month 6 | |
Adhansia XR | 5.4 | 4.2 | 3.0 | 2.4 | 4.8 | 2.9 | 32.0 | 19.7 | 20.1 | 13.5 | 17.8 | 15.9 | 34.1 | 22.4 | 21.8 | 15.8 | 19.7 | 18.4 | 39.7 | 26.1 | 26.1 | 19.5 | 23.6 | 21.9 |
Concerta | 5.6 | 3.7 | 3.2 | 4.7 | 4.9 | 4.1 | 33.3 | 24.2 | 25.0 | 24.6 | 18.3 | 17.6 | 35.5 | 27.2 | 26.4 | 25.3 | 19.5 | 18.9 | 40.9 | 30.1 | 27.1 | 28.6 | 26.3 | 23.5 |
7 reviews available for methylphenidate and Anxiety Neuroses
Article | Year |
---|---|
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.
Topics: Adolescent; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyp | 2019 |
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine H | 2016 |
[Use of psychotropic drugs in children].
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Dis | 2008 |
[Effects of methylphenidate on anxiety].
Topics: Adolescent; Adult; Age Factors; Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention | 2012 |
Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: effects of antidepressants, amphetamine, and methylphenidate.
Topics: Amphetamine; Antidepressive Agents; Anxiety Disorders; Central Nervous System Stimulants; Clinical T | 2003 |
[Conduct disorder, unsocialized and socialized].
Topics: Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2003 |
16 trials available for methylphenidate and Anxiety Neuroses
Article | Year |
---|---|
Methylphenidate modulates interactions of anxiety with cognition.
Topics: Adult; Anxiety; Anxiety Disorders; Cognition; Humans; Memory, Short-Term; Methylphenidate | 2021 |
The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design.
Topics: Adolescent; Adult; Animals; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorder wit | 2014 |
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anxiety Disorders; Apathy; Citalopram; Cognition Disorders; Depressive Disorder, Major; Double | 2015 |
A possible effect of methylphenidate on state anxiety: A single dose, placebo controlled, crossover study in a control group.
Topics: Adult; Anxiety Disorders; Attention; Central Nervous System Stimulants; Control Groups; Cross-Over S | 2016 |
Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2010 |
Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders.
Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2010 |
A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Sys | 2013 |
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2005 |
Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2007 |
Anxiety, methylphenidate response, and working memory in children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response | 1995 |
A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anxiety Disorders; Attention Deficit Disorder with | 1995 |
Response to methylphenidate in children with ADHD and comorbid anxiety.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
Effect of anxiety on cognition, behavior, and stimulant response in ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; D | 1989 |
22 other studies available for methylphenidate and Anxiety Neuroses
Article | Year |
---|---|
Prolonged Postconcussive Symptoms.
Topics: Accidents, Traffic; Adaptation, Psychological; Anxiety Disorders; Attention; Axons; Brain Concussion | 2018 |
Resolution of Anxiety Symptoms in Response to Stimulants in a Patient With Attention-Deficit/Hyperactivity Disorder and Generalized Anxiety Disorder.
Topics: Adult; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2018 |
Childhood narcolepsy and autism spectrum disorders: four case reports.
Topics: Age of Onset; Antidepressive Agents; Anxiety Disorders; Asperger Syndrome; Attention Deficit Disorde | 2018 |
Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder: 2 Case Reports.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2018 |
Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls.
Topics: Adult; Analysis of Variance; Anxiety; Anxiety Disorders; Attention; Attention Deficit Disorder with | 2017 |
Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Comorbidity; Cross-Sectiona | 2016 |
Prevalence, Patient Characteristics, and Pharmacological Treatment of Children, Adolescents, and Adults Diagnosed With ADHD in Sweden.
Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Attention Deficit Disorder with Hyperactivit | 2018 |
Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brain; Causality; Cent | 2009 |
Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder--lack of effect of methylphenidate.
Topics: Action Potentials; Animals; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Diseas | 2009 |
Evaluation of light/dark cycle in anxiety- and depressive-like behaviors after regular treatment with methylphenidate hydrochloride in rats of different ages.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Defic | 2011 |
Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder.
Topics: Achievement; Adolescent; Amphetamine; Anxiety Disorders; Attention Deficit and Disruptive Behavior D | 2011 |
[Attention deficit disorder: multidisciplinary observational study over 1 year].
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Diso | 2003 |
[Considerations on the use of reserpine & phenyl (alpha-piperidyl) acetic acid in the treatment of preoperative anxiety states].
Topics: Acetates; Acetic Acid; Anxiety; Anxiety Disorders; Humans; Methylphenidate; Preoperative Care; Reser | 1957 |
THE TREATMENT OF ANXIETY WITH LYSERGIC ACID AND METHYL PHENIDATE.
Topics: Anxiety; Anxiety Disorders; Humans; Lysergic Acid; Lysergic Acid Diethylamide; Methylphenidate; Neur | 1963 |
MODIFICATIONS IN THE TECHNIQUE OF LSD THERAPY.
Topics: Anxiety; Anxiety Disorders; Brain Chemistry; Drug Therapy; Drug Tolerance; Hospital Design and Const | 1964 |
Treating adolescent girls and women with ADHD: gender-specific issues.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hype | 2005 |
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
Topics: Adult; Aged; Algorithms; Alprazolam; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzod | 2008 |
[Psychotropic drugs for children].
Topics: Amitriptyline; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Ce | 1981 |
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child Psychiatry; | 1995 |
[The influence of the sequence in cross over trials].
Topics: Anxiety Disorders; Chlordiazepoxide; Diazepam; Hospitalization; Humans; Methylphenidate; Placebos | 1968 |